Outcomes of primary refractory multiple myeloma and the impact of novel therapies

Over the past decade, use of novel agents, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) has resulted in high response rates and improvement in overall survival (OS) for patients with multiple myeloma (MM); however, the prognostic significance of refractoriness to these ag...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Am J Hematol
Autores principales: Majithia, Neil, Rajkumar, S. Vincent, Lacy, Martha Q., Buadi, Francis K., Dispenzieri, Angela, Gertz, Morie A., Hayman, Suzanne R., Dingli, David, Kapoor, Prashant, Hwa, Lisa, Lust, John A., Russell, Stephen J., Go, Ronald S., Kyle, Robert A., Kumar, Shaji K.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5801545/
https://ncbi.nlm.nih.gov/pubmed/26214732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24131
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares